FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus

Keyur Patel, Mireen Friedrich-Rust, Yoav Lurie, Mircea Grigorescu, Carol Stanciu, Chuan Mo Lee, Eugene R Schiff, Dieter Häussinger, Michael P. Manns, Guido Gerken, Isabelle Colle, Michael Torbenson, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison, Stefan Zeuzem

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan® transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P < 0.001). Combined FS/TE had 97% accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P < 0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.

Original languageEnglish
Pages (from-to)4581-4589
Number of pages9
JournalWorld Journal of Gastroenterology
Volume17
Issue number41
DOIs
StatePublished - Nov 7 2011

Fingerprint

Elasticity Imaging Techniques
Chronic Hepatitis C
Hepacivirus
Therapeutics
Genotype
Biopsy
Interferons
Sensitivity and Specificity

Keywords

  • Albinterferon alfa-2b
  • FibroScan
  • FibroSURE
  • Hepatitis C virus
  • Interferon
  • Sustained virological response
  • Transient elastography

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Patel, K., Friedrich-Rust, M., Lurie, Y., Grigorescu, M., Stanciu, C., Lee, C. M., ... Zeuzem, S. (2011). FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus. World Journal of Gastroenterology, 17(41), 4581-4589. https://doi.org/10.3748/wjg.v17.i41.4581

FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus. / Patel, Keyur; Friedrich-Rust, Mireen; Lurie, Yoav; Grigorescu, Mircea; Stanciu, Carol; Lee, Chuan Mo; Schiff, Eugene R; Häussinger, Dieter; Manns, Michael P.; Gerken, Guido; Colle, Isabelle; Torbenson, Michael; Pulkstenis, Erik; Mani Subramanian, G.; McHutchison, John G.; Zeuzem, Stefan.

In: World Journal of Gastroenterology, Vol. 17, No. 41, 07.11.2011, p. 4581-4589.

Research output: Contribution to journalArticle

Patel, K, Friedrich-Rust, M, Lurie, Y, Grigorescu, M, Stanciu, C, Lee, CM, Schiff, ER, Häussinger, D, Manns, MP, Gerken, G, Colle, I, Torbenson, M, Pulkstenis, E, Mani Subramanian, G, McHutchison, JG & Zeuzem, S 2011, 'FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus', World Journal of Gastroenterology, vol. 17, no. 41, pp. 4581-4589. https://doi.org/10.3748/wjg.v17.i41.4581
Patel, Keyur ; Friedrich-Rust, Mireen ; Lurie, Yoav ; Grigorescu, Mircea ; Stanciu, Carol ; Lee, Chuan Mo ; Schiff, Eugene R ; Häussinger, Dieter ; Manns, Michael P. ; Gerken, Guido ; Colle, Isabelle ; Torbenson, Michael ; Pulkstenis, Erik ; Mani Subramanian, G. ; McHutchison, John G. ; Zeuzem, Stefan. / FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus. In: World Journal of Gastroenterology. 2011 ; Vol. 17, No. 41. pp. 4581-4589.
@article{5fd58a31b841425085c762a6802f8c85,
title = "FibroSURE™ and FibroScan{\circledR} in relation to treatment response in chronic hepatitis C virus",
abstract = "AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan{\circledR} transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71{\%} (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P < 0.001). Combined FS/TE had 97{\%} accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P < 0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.",
keywords = "Albinterferon alfa-2b, FibroScan, FibroSURE, Hepatitis C virus, Interferon, Sustained virological response, Transient elastography",
author = "Keyur Patel and Mireen Friedrich-Rust and Yoav Lurie and Mircea Grigorescu and Carol Stanciu and Lee, {Chuan Mo} and Schiff, {Eugene R} and Dieter H{\"a}ussinger and Manns, {Michael P.} and Guido Gerken and Isabelle Colle and Michael Torbenson and Erik Pulkstenis and {Mani Subramanian}, G. and McHutchison, {John G.} and Stefan Zeuzem",
year = "2011",
month = "11",
day = "7",
doi = "10.3748/wjg.v17.i41.4581",
language = "English",
volume = "17",
pages = "4581--4589",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "41",

}

TY - JOUR

T1 - FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus

AU - Patel, Keyur

AU - Friedrich-Rust, Mireen

AU - Lurie, Yoav

AU - Grigorescu, Mircea

AU - Stanciu, Carol

AU - Lee, Chuan Mo

AU - Schiff, Eugene R

AU - Häussinger, Dieter

AU - Manns, Michael P.

AU - Gerken, Guido

AU - Colle, Isabelle

AU - Torbenson, Michael

AU - Pulkstenis, Erik

AU - Mani Subramanian, G.

AU - McHutchison, John G.

AU - Zeuzem, Stefan

PY - 2011/11/7

Y1 - 2011/11/7

N2 - AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan® transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P < 0.001). Combined FS/TE had 97% accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P < 0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.

AB - AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan® transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P < 0.001). Combined FS/TE had 97% accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P < 0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.

KW - Albinterferon alfa-2b

KW - FibroScan

KW - FibroSURE

KW - Hepatitis C virus

KW - Interferon

KW - Sustained virological response

KW - Transient elastography

UR - http://www.scopus.com/inward/record.url?scp=82155187178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155187178&partnerID=8YFLogxK

U2 - 10.3748/wjg.v17.i41.4581

DO - 10.3748/wjg.v17.i41.4581

M3 - Article

VL - 17

SP - 4581

EP - 4589

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 41

ER -